Drugs, Public Health, and the Patent Linkage System in India and Japan
DOI:
https://doi.org/10.69971/tipr.2.2.2024.29Keywords:
Patents, Patent Linkage, Generic Drugs, TRIPS, medicinesAbstract
We may often come across mind boggling, incomprehensible doctor prescriptions quite difficult to decipher, with new drug names for the common flu and the usual ‘paracetamols’ found in other drugs under many different labels and names. This indicates nothing but the existence of a generic drug system. Generic drugs have same chemical formulas, properties and compositions as that of originator drugs or products. TRIPS plus concept of linking the drug regulatory authority and the patent authorities is prevalent in many states, emphasizing the prevention of generic drugs. This article will focus on patent linkage system of Japan and India and its functional details in these countries. The Japanese system is flexible, allowing the entry of generic drugs on certain conditions at the discretion of the Ministry of Health, Labor & Welfare and the results of the Japanese Patent Office. The uncertainties create a confusing view on the patent linkage system in Japan. The definition of original drugs and generic drugs are not clear in any of the provisions regulating the same, and permission or the prohibition of generic drugs or the determination of the status of a drug depends entirely on the ministries. Indian system, however, does not prohibit the entry of generics and promotes the usage of generics through various schemes, circulars and laws. It encourages doctors to prescribe the same for easy access to generic medicines. The article explores the contradicting provisions about generic drugs stipulated by the drugs & cosmetics act, 1940, expands on the bolar provisions in place and analyses the shortcomings of the system allowing generic drugs in India. The study highlights the need for a patent linkage system, supported by proper justifications and the concepts that could be implemented, for the effective functioning of both the drug regulatory authorities and the intellectual property authorities, protecting the interests of the patent owners as well as the common public, consequently.
References
Anonymous. 2024.Legislation-update, changes to patent Linkage System in Singapore. https://www.twobirds.com/en/patenthub/shared/insights/2024/singapore/legislation-update-changes-to-patent-linkage-system-in-singapore
APEC. 2023. Patent linkage system for intellectual property rights and public health harmonisation, Intellectual property Rights Experts Group. https://www.apec.org/docs/default-source/publications/2023/7/223_ipeg_patent-linkage-system-for-intellectual-property-rights-and-public-health-harmonisation.pdf
Gao, Gordon, Yao Sherry.2024. Navigating Chinas New Protections For life Science Patents, Asia Business Law Journal, https://www.jonesday.com/en/insights/2021/09/patent-linkage-and-article-76-proceedings-in-china-a-litigators-perspective
Hino, Mami, Ebata Naho, Kajinami Shoichiro. 2024. Japan: Sawai’s Generic Drug is approved by the MHLW amid patent litigation with Bristol Myers Squibb, but the court orders preliminary injunction against Sawai soon af-ter,https://patentblog.kluweriplaw.com/2024/01/09/japan-sawais-generic-drug-is-approved-by-the-mhlw-amid-patent-litigation-with-bristol-myers-squibb-but-the-court-orders-preliminary-injunction-against-sawai-soon-after/
Kumar Bhumika, Chandra Akhilesh. 2016. A comparative study of the drug approval process in USA, India, Japan and Europe. World journal of pharmaceutical Research 6: 311-322.
Lida, Masato.2022. Patent linkage in Japan: the present situation and challenges, Available at :https://www.managingip.com/article/2axkxcw96suati6wv2znk/sponsored-content/patent-linkage-in-japan-the-present-situation-and-challenges.
Mishra, Sukeerti Samalei. 2023.Global perspectives On Patent Linkage:Insights from the US, Europe and India, https://www.iiprd.com/global-perspectives-on-patent-linkage-insights-from-the-us-europe-and-india/
Shin, Hie Eun.2019. Comparative study on patent linkage system. Institute of Intellectual Property, Japan. https://www.iip.or.jp/e/summary/pdf/detail2018/EN_Abstract_Summary_Shin.pdf20 January 2025.
Winninger, Aaron R, Chanf Austin, Wininger Carol.2021.Chinas New Patent linkage System: A guide for Foreign Chinese Patent hold-ers.https://ipwatchdog.com/2021/07/22/chinas-new-patent-linkage-system-a-guide-for-foreign-chinese-patent-holders/id=135673/
Yao, Xue-Fang.2024. Characteristics and outcomes of the drug patent linkage system in China. Global Health 20:1-11, https://doi.org/10.1186/s12992-024-01035-x
Yu, Choo Chio.2024. Updates to Patent Drug linkage System clarifies clarification requirements. https://www.spruson.com/singapore-updates-to-patent-drug-linkage-system-clarifies-declaration-requirements/
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Authors

This work is licensed under a Creative Commons Attribution 4.0 International License.